Literature DB >> 9476972

Effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol.

J M Kirk1, P Doty, H De Wit.   

Abstract

The effects of expectancies on subjective responses to oral delta9-tetrahydrocannabinol (delta9-THC) were examined. Thirty-five regular marijuana users were assigned to one of two groups: one group was told that they may receive a cannabinoid or placebo and a second group was told that they may receive a drug from one of several classes of drugs (e.g., stimulant, sedative, antiemetic) or placebo. Regardless of the group to which they were assigned, subjects received each of two oral doses of delta9-THC (7.5 and 15 mg) and placebo, one dose per session, for a total of three sessions. Measures of subjective effects, including visual analog scales and the Addiction Research Center Inventory (ARCI), were administered at 0.5-h intervals throughout each session. Consistent with previous research using other drugs, subjects in the current experiment who expected to receive a cannabinoid reported greater pleasurable effects than subjects who did not have this expectancy. The results have implications for understanding the effects of cannabinoids when used in both recreational and clinical settings.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9476972     DOI: 10.1016/s0091-3057(97)00414-0

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  33 in total

Review 1.  The addicted human brain: insights from imaging studies.

Authors:  Nora D Volkow; Joanna S Fowler; Gene-Jack Wang
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

Review 2.  The endocannabinoid system as a target for modelling psychosis.

Authors:  Dagmar Koethe; Carolin Hoyer; F Markus Leweke
Journal:  Psychopharmacology (Berl)       Date:  2009-06-16       Impact factor: 4.530

3.  Beliefs modulate the effects of drugs on the human brain.

Authors:  Nora D Volkow; Ruben Baler
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-11       Impact factor: 11.205

Review 4.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

5.  Expectation to receive methylphenidate enhances subjective arousal but not cognitive performance.

Authors:  Alison Looby; Mitch Earleywine
Journal:  Exp Clin Psychopharmacol       Date:  2011-08-29       Impact factor: 3.157

6.  Subjective effects to marijuana associated with marijuana use in community and clinical subjects.

Authors:  Joanna S Zeiger; Brett C Haberstick; Robin P Corley; Marissa A Ehringer; Thomas J Crowley; John K Hewitt; Christian J Hopfer; Michael C Stallings; Susan E Young; Soo Hyun Rhee
Journal:  Drug Alcohol Depend       Date:  2010-02-09       Impact factor: 4.492

Review 7.  Self-administration of cannabinoids by experimental animals and human marijuana smokers.

Authors:  Zuzana Justinova; Steven R Goldberg; Stephen J Heishman; Gianluigi Tanda
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

8.  The subjective psychoactive effects of oral dronabinol studied in a randomized, controlled crossover clinical trial for pain.

Authors:  Mohammed A Issa; Sanjeet Narang; Robert N Jamison; Edward Michna; Robert R Edwards; David M Penetar; Ajay D Wasan
Journal:  Clin J Pain       Date:  2014-06       Impact factor: 3.442

9.  Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study.

Authors:  Celia J A Morgan; Ali Mofeez; Brigita Brandner; Lesley Bromley; H Valerie Curran
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

10.  Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers.

Authors:  Nora D Volkow; Gene-Jack Wang; Yemin Ma; Joanna S Fowler; Wei Zhu; Laurence Maynard; Frank Telang; Paul Vaska; Yu-Shin Ding; Christopher Wong; James M Swanson
Journal:  J Neurosci       Date:  2003-12-10       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.